OakChart

Monte Rosa Therapeutics Inc

GLUEHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 1:43 PM ET

10.30-0.20 (-1.95%)
2026-11-11 19:44 CET
Market cap
897.23 USD m
Revenue, TTM
70.33 USD m
Net income, TTM
-130.97 USD m
Free cash flow, TTM
-174.39 USD m
EPS diluted, TTM
-1.55
P/E
-
Compare

Price

GLUE against its 20, 50 and 200-day averages
2050200beatmiss
10.0015.0020.0025.003.7M7.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GLUEclose 10.3020-day 10.6450-day 11.50200-day 16.8610.3052w high

60.1% under the 52-week high of 25.77 on 8 Jan 2026. 52-week low 9.68 on 7 Oct 2026. Last 15 sessions, 15.3% high to low

Profile

GLUE
52-week range, 4% of the way up
9.6825.77

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

IndexRUT
Employees150
IPOJun 24, 2021
Beta1.39
ATR, 14d0.62
Rel volume0.33
Short float34.61%
Insider own29.47%
Inst own88.84%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap879.71M
Enterprise Value338.25M
Income-130.97M
Sales70.33M
Book/sh5.81
Cash/sh6.76
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees150
IPOJun 24, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S12.51
P/B1.77
P/C1.52
P/FCF-
EV/EBITDA-
EV/Sales4.81
Quick Ratio10.32
Current Ratio10.32
Debt/Eq0.07
LT Debt/Eq0.06
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.55
EPS next Y-1.80
EPS next Q-0.21
EPS this Y-128.22%
EPS next Y-71.90%
EPS next 5Y-
EPS past 3/5Y41.29% 10.62%
Sales past 3/5Y- -
EPS Y/Y TTM-597.59%
Sales Y/Y TTM-61.26%
EPS Q/Q108.58%
Sales Q/Q325.80%
EarningsNov 05 BMO
EPS/Sales Surpr.0.00% 0.00%

Ownership

Insider Own29.47%
Insider Trans-0.47%
Inst Own88.84%
Inst Trans6.49%
ROA-22.63%
ROE-35.30%
ROIC-24.79%
Gross Margin88.38%
Oper. Margin-214.46%
Profit Margin-186.24%
SMA20-3.21%
SMA50-10.47%
SMA200-38.94%
Trades-

Technical

Shs Outstand85.43M
Shs Float60.26M
Short Float34.61%
Short Ratio16.05
Short Interest20.86M
52W High25.77 -60.05%
52W Low9.68 6.35%
Volatility6.52% 5.75%
ATR (14)0.62
RSI (14)41.72
Beta1.39
Rel Volume0.33
Avg Volume1.30M
Volume287,153

Performance

Perf Week-4.85%
Perf Month4.10%
Perf Quarter-35.01%
Perf Half Y-45.70%
Perf YTD-34.34%
Perf Year-28.11%
Perf 3Y220.72%
Perf 5Y-58.18%
Perf 10Y-
Recom1.00
Target Price25.38
Prev Close10.50
Price10.30
Change %-1.95%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Oct 01, 2026InitiatedHH.C. WainwrightBuy$25+142.8%
Dec 19, 2024DowngradeWWells FargoOverweight → Equal Weight$14 → $11+6.8%
Feb 15, 2024InitiatedWWedbushOutperform$11+6.8%
Jan 03, 2023UpgradeWWells FargoEqual Weight → Overweight$18+74.8%
Oct 13, 2022InitiatedUUBSBuy$22+113.7%
Aug 15, 2022InitiatedJJefferiesBuy$20+94.3%
Apr 28, 2022InitiatedCCredit SuisseNeutral$19+84.6%
Feb 10, 2022InitiatedWWells FargoEqual Weight$19+84.6%
Oct 14, 2021InitiatedSSVB LeerinkMkt Perform$20+94.3%

Peers

Mkt cap
TickerCompanyMkt cap
NRIXNurix Therapeutics Inc1.82B
ARVNArvinas Inc451.18M
CCCCC4 Therapeutics Inc382.13M
KYMRKymera Therapeutics Inc11.61B
IDYAIdeaya Biosciences Inc3.14B
RCUSArcus Biosciences Inc2.70B
RVMDRevolution Medicines Inc39.50B
TNGXTango Therapeutics Inc4.45B
ZNTLZentalis Pharmaceuticals Inc186.71M
BMYBristol-Myers Squibb Co127.19B

Insider trading

latest 14 of 77
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Bowen MatthewPrincipal Accounting OfficerOct 05 '26Sale10.561313725,891Oct 06 04:05 PM
Warmuth MarkusPresident & CEOJul 16 '26Sale23.189,500220,219585,038Jul 17 04:05 PM
Champoux JenniferChief Operating OfficerJul 15 '26Option Exercise3.984,35117,31766,722Jul 16 04:10 PM
Champoux JenniferChief Operating OfficerJul 15 '26Sale23.384,351101,73062,371Jul 16 04:10 PM
MARKUS WARMUTHOfficerJul 16 '26Proposed Sale23.189,500220,219Jul 16 04:05 PM
Champoux JenniferOfficerJul 15 '26Proposed Sale23.384,351101,730Jul 15 04:12 PM
Townson SharonChief Scientific OfficerJul 06 '26Option Exercise6.146,00036,84073,845Jul 07 04:41 PM
Townson SharonChief Scientific OfficerJul 06 '26Sale23.316,000139,84967,845Jul 07 04:41 PM
Janku FilipChief Medical OfficerJun 30 '26Option Exercise13.415,40772,50866,019Jul 01 04:57 PM
Janku FilipChief Medical OfficerJun 30 '26Sale24.505,407132,47260,612Jul 01 04:57 PM
FILIP JANKUOfficerJun 30 '26Proposed Sale23.905,407129,227Jun 30 04:38 PM
Janku FilipChief Medical OfficerJun 29 '26Option Exercise7.566,00045,36065,992Jun 30 04:05 PM
Janku FilipChief Medical OfficerJun 29 '26Sale22.956,000137,70059,992Jun 30 04:05 PM
Manning Anthony M.DirectorJun 29 '26Option Exercise4.1610,00041,60010,000Jun 30 04:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
TMSLT. Rowe Price Small-Mid Cap ETFAUM: 3.28B

News

latest 14 of 200
  • Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout (GlobeNewswire)
  • Monte Rosa Therapeutics: Q3 Earnings Snapshot (Associated Press) -5.27%
  • Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
  • Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) (GlobeNewswire)
  • Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.75%
  • Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk (GlobeNewswire) -5.62%
  • Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk (GlobeNewswire)
  • Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) (GlobeNewswire)
  • Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
  • Monte Rosa Therapeutics: Q2 Earnings Snapshot (Associated Press)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.215-0.2150.02833.8733.879
2026Q22026-08-06-0.430-0.381-0.4288.9912.917
2026Q12026-05-07-0.446-0.388-0.4464.1810.957
2025Q42026-03-17-0.543-0.352-0.7042.8315.557
2025Q32025-11-06-0.330-0.366-0.32912.817.377
2025Q22025-08-07-0.150-0.377-0.15023.177.388
2025Q12025-05-110.570-0.0030.56584.9341.687
2024Q42025-03-200.1700.0160.21960.6746.679
2024Q32024-11-07-0.290-0.475-0.2919.142.647
2024Q22024-08-08-0.430-0.521-0.4264.801.357
2024Q12024-05-09-0.530-0.584-0.5311.071.408
2023Q42024-03-14-0.580-0.387-0.5840.003.538
2023Q32023-11-09-0.700-0.724-0.7000.000.008
2023Q22023-08-10-0.710-0.697-0.7120.000.008
2023Q12023-05-11-0.650-0.681-0.6490.000.008
2022Q42023-03-16-0.630-0.624-0.6300.000.009

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-2.960-2.608-1.5890.000.00
2022FY-2.300-2.282-2.2970.000.00
2023FY-2.630-2.403-2.6340.003.53
2024FY-0.979-1.255-0.98475.6659.79
2025FY-0.465-0.258-0.465123.73136.47
2026FY--1.050--103.14
2027FY--1.805--62.13
2028FY--1.627--120.83
2029FY--2.242--116.07
2030FY--2.180--138.77

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0595035.660.00123
2026Q4S2026-10-2792025.820.00110.87
2026Q4S2026-10-2091021.650.00110.87
2026Q4S2026-10-0993121.650.00110.87
2026Q4S2026-09-3083123.160.00110.87
2026Q4S2026-09-0472121.610.00110.87
2026Q4S2026-08-0672121.620.00110.87
2026Q4S2026-07-2270013.680.0062.59
2026Q4S2026-07-2171013.680.0062.59
2026Q4S2026-07-1972013.680.0062.59
2026Q4S2026-05-3172113.680.0062.59
2026Q4S2026-05-0872213.680.0062.59
2026Q4S2026-05-0771212.910.0057.25
2026Q4S2026-05-0571212.790.0057.25

Estimate history

EPS, annual-0.176-0.815-1.589-2.297-2.634-0.984-0.465-1.5489
Period2019202020212022202320242025TTM
EPS, quarterly-0.2910.2190.565-0.15-0.329-0.704-0.446-0.4280.028
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000075.622123.67270.33
Period2019202020212022202320242025TTM
Sales, quarterly9.21660.64784.92923.19412.7682.7814.218.96854.366
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual44.00344.00346.53649.32450.1461.50765.54485.431
Period2019202020212022202320242025MRQ
Shares, quarterly61.37761.50761.5161.71761.7965.54484.32285.22685.431
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue70.33123.6775.620.000.000.000.000.00
Cost of Goods Sold Incl. D&A8.178.368.126.228.562.130.540.07
Gross Profit62.15115.3267.50-6.22-8.56-2.13-0.54-0.07
Selling, General and Administrative Excl. Other212.97169.52148.61137.09103.8370.7527.477.92
Research and Development171.20133.14113.44105.0576.5055.0223.477.28
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-150.82-54.21-81.11-143.31-112.38-72.88-28.01-7.99
Interest Expense0.000.000.000.000.000.00--
Unusual Expense0.000.000.000.000.000.967.68-
Net Income Before Taxes-129.94-39.72-70.13-135.01-108.50-73.96-35.88-7.74
Income Taxes1.03-1.102.570.340.000.000.000.00
Consolidated Net Income-130.97-38.63-72.70-135.35-108.50-73.96-35.88-7.74
Net Income From Continuing Operations-130.97-38.63-72.70-135.35-108.50-73.96-35.88-7.74
Net Income-130.97-38.63-72.70-135.35-108.50-73.96-35.88-7.74
EPS (Recurring)-1.21-0.46-0.98-2.63-2.30-1.57-0.69-0.18
EPS (Basic, Before Extraordinaries)-1.55-0.47-0.98-2.63-2.30-1.59-0.82-0.18
EPS (Diluted)-1.55-0.47-0.98-2.63-2.30-1.59-0.82-0.18
EBITDA-142.65-45.85-72.99-137.09-103.83-70.75-27.47-7.92
Non-Operating Income (Expense)20.8814.4810.988.303.88-0.12-0.190.26
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense17.8214.9014.3213.1711.665.200.350.00
Price To Sales Ratio18.4310.536.78-----
Gross Margin88.3893.2489.26-----
Operating Margin-214.46-43.83-107.26-----
Net Margin-186.24-31.23-96.14-----
Shares Outstanding85.4365.5461.5150.1449.3246.5444.0044.00
Market Capitalization897.23897.23426.37282.96368.32949.65971.97-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue54.378.974.212.7812.7723.1984.9360.65
Cost of Goods Sold Incl. D&A2.141.912.032.092.102.122.052.06
Gross Profit52.227.062.180.6910.6721.0782.8858.59
Selling, General and Administrative Excl. Other54.1656.1952.2250.4143.6536.6238.8445.58
Research and Development43.2246.0542.0439.8934.5828.5330.1436.80
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.94-49.13-50.03-49.72-32.98-15.5544.0413.00
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes3.78-43.19-44.45-46.08-30.26-11.1047.7115.60
Income Taxes0.720.210.050.06-3.181.200.822.16
Consolidated Net Income3.06-43.40-44.50-46.13-27.08-12.2946.8813.44
Net Income From Continuing Operations3.06-43.40-44.50-46.13-27.08-12.2946.8813.44
Net Income3.06-43.40-44.50-46.13-27.08-12.2946.8813.44
EPS (Recurring)0.03-0.43-0.45-0.70-0.33-0.150.570.22
EPS (Basic, Before Extraordinaries)0.03-0.43-0.45-0.70-0.33-0.150.570.22
EPS (Diluted)0.03-0.43-0.45-0.70-0.33-0.150.570.22
EBITDA0.20-47.22-48.01-47.63-30.88-13.4346.0815.06
Non-Operating Income (Expense)5.725.945.583.642.724.463.672.60
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.004.724.703.403.453.874.193.53
Price To Earnings Ratio---51.3421.6067.11--
Price To Sales Ratio18.4385.4938.258.313.362.082.415.64
Gross Margin96.0678.6951.8124.9283.5990.8497.5996.60
Operating Margin-3.57-547.84-1,188.46-1,787.67-258.26-67.0651.8521.44
Net Margin5.63-483.91-1,057.08-1,658.94-212.10-53.0155.2022.16
Shares Outstanding85.4385.2384.3265.5461.7961.7261.5161.51
Market Capitalization897.232,044.401,316.261,021.05457.64277.41285.41426.37

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments377.10372.15232.41263.79346.0741.709.24
Short Term Receivables11.600.170.517.660.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets4.485.123.294.442.601.890.51
Total Current Assets393.19377.44236.21275.89348.6743.599.76
Net Property, Plant & Equipment50.3756.3162.6161.9112.324.621.33
Total Investments and Advances4.954.864.584.325.341.160.00
Intangible Assets----0.000.000.00
Other Assets0.150.120.350.280.000.000.00
Total Assets448.66438.73303.75342.39366.3349.3811.09
Short Term Debt Incl. Current Port. of LT Debt4.403.713.163.130.000.000.00
Accounts Payable3.5517.2111.157.866.567.073.19
Other Current Liabilities56.27136.0232.2814.5810.0822.211.10
Total Current Liabilities64.21156.9546.5925.5716.6429.274.29
Long Term Debt34.7939.0042.8843.870.0067.7618.95
Provision for Risks Charges5.263.702.711.532.180.000.00
Other Liabilities111.3316.1532.320.000.001.070.00
Total Liabilities215.60215.80124.5070.9818.8198.1123.24
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity233.06222.94179.25271.41347.51-48.73-12.15
Total Shareholders Equity233.06222.94179.25271.41347.51-48.73-12.15
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity233.06222.94179.25271.41347.51-48.73-12.15
Total Liabilities & Stockholders Equity448.66438.73303.75342.39366.3349.3811.09
Book Value Per Share3.563.623.575.507.47-1.11-0.28
Tangible Book Value Per Share3.563.623.575.507.47-1.11-0.28
Full-Time Employees15013413312393--
Price to Book Ratio1.812.071.531.262.732.63-
Return on Assets-8.71-19.58-41.90-30.62-35.58-118.66-
Return on Equity-16.94-36.15-60.07-35.06-49.51--
Return on Invested Capital-14.42-27.75-60.93-34.41-21.28-188.48-113.79
Quick Ratio6.122.405.0710.7920.961.492.27
Current Ratio6.122.405.0710.7920.961.492.27

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-130.97-38.63-72.70-135.35-108.50-73.96-35.88-7.74
Depreciation8.188.368.126.228.562.130.540.07
Other Funds (Non Cash)21.0316.6615.1812.869.616.188.03-0.28
Funds from Operations-101.77-13.61-49.40-116.27-90.33-65.65-27.31-7.94
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-63.71-9.1991.4072.47-2.136.294.251.77
Cash from Operating Activities-165.47-22.8042.00-43.80-92.47-59.36-23.05-6.17
Capital Expenditures-8.92-4.70-3.99-19.04-12.91-9.73-3.39-1.39
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.060.110.080.000.00
Purchase or Sale of Investments-350.54-97.13-40.46107.78-206.420.000.000.00
Purchase of Investments-653.44-376.68-230.36-103.15-384.420.000.000.00
Sale Or Maturity of Investments302.89279.54189.90210.93178.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-359.46-101.83-44.4588.80-219.22-9.65-3.39-1.39
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock361.7430.3598.8927.4920.47377.5660.0614.25
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock361.7430.3598.8927.4920.47377.5660.0614.25
Proceedsfrom Stock Options348.6924.6397.8325.4620.03377.4160.0614.25
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.75
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities361.7430.3598.8927.4920.47377.5660.0615.00
Net Change in Cash-163.19-94.2896.4472.49-291.22308.5533.627.44
Free Cash Flow-174.39-27.5038.01-62.78-105.38-69.09-26.44-7.56
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Price to Free Cash Flow--13.50-----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments577.73621.10666.22377.10391.26290.59
Short Term Receivables57.624.924.6111.604.962.37
Inventories0.000.000.000.000.000.00
Other Current Assets4.715.386.724.485.596.50
Total Current Assets640.07631.41677.55393.19401.82299.46
Net Property, Plant & Equipment51.9853.9953.1050.3752.6654.73
Total Investments and Advances4.924.944.954.954.954.95
Other Assets0.770.830.830.150.410.45
Total Assets697.73691.16736.43448.66459.84359.59
Short Term Debt Incl. Current Port. of LT Debt4.194.634.484.404.244.09
Accounts Payable3.357.157.903.5514.515.58
Income Tax Payable3.02-----
Other Current Liabilities51.4947.8858.6556.2742.6932.18
Total Current Liabilities62.0559.6671.0464.2161.4441.85
Long Term Debt32.0833.3634.5834.7935.9337.04
Provision for Risks Charges5.135.245.265.264.744.56
Other Liabilities102.26105.62103.64111.33111.898.06
Total Liabilities201.52203.88214.51215.60214.0091.51
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity496.21487.28521.92233.06245.84268.08
Total Shareholders Equity496.21487.28521.92233.06245.84268.08
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity496.21487.28521.92233.06245.84268.08
Total Liabilities & Stockholders Equity697.73691.16736.43448.66459.84359.59
Book Value Per Share5.815.726.193.563.984.34
Tangible Book Value Per Share5.815.726.193.563.984.34
Full-Time Employees---150147142
Price to Book Ratio1.813.914.633.941.711.01
Return on Assets-22.63-30.67-23.02-8.715.416.87
Return on Equity-35.30-42.66-32.62-16.949.289.81
Return on Invested Capital0.58-8.34-8.00-17.22-9.61-4.03
Quick Ratio10.3210.589.546.126.547.16
Current Ratio10.3210.589.546.126.547.16

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income3.06-43.40-44.50-46.13-27.08-12.29
Depreciation2.141.912.032.092.102.12
Other Funds (Non Cash)6.675.004.964.403.904.16
Funds from Operations11.88-36.49-37.51-39.65-21.09-6.01
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-52.86-7.630.14-3.36121.52-28.71
Cash from Operating Activities-40.98-44.11-37.37-43.01100.43-34.72
Capital Expenditures-1.56-4.72-1.87-0.77-0.65-1.70
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-2.98-24.14-259.13-64.3038.7927.02
Purchase of Investments-91.71-76.07-332.00-153.66-65.97-19.03
Sale Or Maturity of Investments88.7351.9472.8789.36104.7646.05
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-4.54-28.86-261.00-65.0738.1425.32
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.573.21328.3329.620.350.36
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.573.21328.3329.620.350.36
Proceedsfrom Stock Options0.000.61323.8124.260.000.36
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.573.21328.3329.620.350.36
Net Change in Cash-44.95-69.7629.97-78.46138.91-9.03
Free Cash Flow-42.54-48.84-39.24-43.7899.78-36.41
Price to Free Cash Flow----4.2115.54

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 75.62M 2025: 123.67M
United States2024: 75.62M 2025: 123.67M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3034.61%20.9M60.3M1.40M
2026-10-1534.34%20.7M60.2M1.36M
2026-09-3032.72%19.7M60.2M1.27M
2026-09-1532.02%19.3M60.2M1.44M
2026-08-3130.17%18.1M59.9M1.42M
2026-08-1429.13%17.5M59.9M1.39M
2026-07-3127.27%16.5M60.4M1.30M
2026-07-1528.77%17.2M59.8M1.16M
2026-06-3031.72%18.6M58.8M1.12M
2026-06-1529.21%17.2M58.8M1.02M
2026-05-2927.22%16.0M58.8M990.05K
2026-05-1525.85%15.0M57.9M1.02M
2026-04-3026.47%15.1M57.2M1.07M
2026-04-1532.40%15.8M48.9M1.12M
2026-03-3127.42%13.4M48.9M1.65M
2026-03-1322.44%11.0M48.9M1.63M
2026-02-2721.72%10.1M46.6M1.59M
2026-02-1320.04%9.3M46.6M1.58M
2026-01-3016.06%7.7M47.7M1.58M
2026-01-1511.64%5.6M47.7M1.55M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.505.6010.000.0024.6150.000.000.986-0.0160.001
call5.005.105.905.295.3590.006.000.974-0.0150.001
call7.502.005.003.206.5991.000.000.948-0.0130.002
call10.000.400.750.600.9202,9983.000.600-0.0440.006
call12.500.000.600.242.0342,2092.000.328-0.0670.006
call15.000.000.250.132.0693262.000.162-0.0460.004
call17.500.004.100.002.5800.000.000.138-0.0510.004
call20.000.004.100.002.9630.000.000.124-0.0550.003
call22.500.004.100.003.3200.000.000.115-0.0580.003
call25.000.004.100.003.6280.000.000.108-0.0610.003
put2.500.004.100.0010.5650.000.00-0.046-0.0920.002
put5.000.004.100.055.8302.000.00-0.104-0.0950.003
put7.500.000.050.003.3000.000.00-0.195-0.0810.004
put10.000.050.750.401.40510.000.00-0.403-0.0430.006
put12.501.952.552.051.6073.004.00-0.672-0.0650.006
put15.002.506.900.005.3750.000.00-0.839-0.0450.004
put17.505.009.306.355.9110.000.00-0.862-0.0500.004
put20.007.5011.900.006.5980.000.00-0.876-0.0540.003
put22.5010.0014.400.007.0120.000.00-0.885-0.0570.003
put25.0012.5016.900.007.4250.000.00-0.891-0.0590.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-018-KCurrent report2026-10-01SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-16144Filing for proposed sale of securities under Rule 144.SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-15144Filing for proposed sale of securities under Rule 144.SEC
2026-07-08SCHEDULE 13G/ASEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-06SCHEDULE 13D/ASEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-24144Filing for proposed sale of securities under Rule 144.SEC
2026-06-23144Filing for proposed sale of securities under Rule 144.SEC
2026-06-23144Filing for proposed sale of securities under Rule 144.SEC
2026-06-23144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10001371
2026-090000
2026-080000
2026-0700461.80K3
2026-06001.69M10
2026-0500487.61K5
2026-0400244.54K2
2026-0300109.85K3
2026-0200634.67K2
2026-0100433.49K6
2025-120000
2025-110000

Institutional holders

Manager% owned
PRICE T ROWE ASSOCIATES INC /MD/10.49%
NEA Management Company, LLC9.11%
BlackRock, Inc.8.10%
TCG Crossover Management, LLC5.47%
Vestal Point Capital, LP5.45%
BVF INC/IL5.28%
BAKER BROS. ADVISORS LP5.14%
STATE STREET CORP4.42%
MONTANOVA CAPITAL, LLC4.20%
VANGUARD CAPITAL MANAGEMENT LLC4.04%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
T. Rowe Price New Horizons Fund, Inc.2.64%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.50%
iShares Russell 2000 ETF2.25%
T. Rowe Price Health Sciences Fund, Inc.2.16%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1.63%
Fidelity Small Cap Index Fund0.96%
VANGUARD EXTENDED MARKET INDEX FUND0.93%
iShares Russell 2000 Growth ETF0.77%
VANGUARD EXPLORER FUND0.63%

OakChart. GLUE. Cached 15 minutes.